Table S3A/B/C/D: Clinical summary of GLASS epigenomic samples S3A: Clinical summary of IDHmut patients who switched from GCIMP-high to GCIMP-low S3B: Clinical summary of IDHmut and IDHwt patients wit
Despite decades of research, standard therapies remain ineffective for most leukemias, pushing toward an essential unmet need for targeted drug screens. Moreover, preclinical drug testing is an import
This study is being done to determine the dose of a chemotherapy drug (irinotecan [irinotecan hydrochloride]) that can be tolerated as part of a combination of drugs. There is a combination of chemoth
